| 1 |
31135266 | HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment. | 2019 Jul |
4 |
| 2 |
31164152 | Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. | 2019 Jun 4 |
1 |
| 3 |
28881779 | The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer. | 2017 Aug 8 |
2 |
| 4 |
27573562 | Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. | 2016 Nov |
1 |
| 5 |
25471734 | Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. | 2015 Jul 15 |
3 |
| 6 |
24601221 | More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro. | 2014 Jan |
4 |
| 7 |
22553357 | ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo. | 2012 Jul |
1 |
| 8 |
20453058 | Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. | 2010 Jul 15 |
1 |
| 9 |
20538763 | PIKing the right patient. | 2010 Jul 15 |
1 |
| 10 |
19411071 | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. | 2009 May 5 |
1 |
| 11 |
19509167 | Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. | 2009 Jun 15 |
4 |